

ASX / Media Release

9 November 2009

RHT: Additional FerriScan[®] Revenue and International Conference Presentations

Resonance Health Limited (ASX: RHT) is pleased to announce it has been awarded additional contracts to the value of nearly US\$500,000 for the delivery of FerriScan services to the pharmaceutical industry over the next two years.

FerriScan is now considered by many in the medical and scientific community as the 'gold standard' in the measurement of iron overload and is used extensively in both the clinical setting and in trials for iron chelator drug therapies.

FerriScan has recently been showcased at the Sickle Cell Society of America Convention, September 30 – October 3 in Orlando, USA. Approximately 100,000 people in the United States have the sickle cell disease and a portion of these become iron loaded due to receiving regular blood transfusions. The sickle cell disease market in the USA represents a significant opportunity for FerriScan.

FerriScan was also showcased at the New York Academy of Science, Ninth Cooley's Anemia Symposium, held in New York on October 21-24, 2009. Chief Scientific Officer, Dr St Pierre was an invited speaker at the Symposium highlighting the important of the FerriScan technology and Dr St Pierre's international reputation in this field of medicine.

Additionally, Dr St Pierre was an invited speaker at the American Association for the Study of Liver Disease held in Boston on October 30 – November 3, 2009. The conference was attended by over 7,000 health professionals from around the world discussing the latest in liver research and treatment options.

These conferences represent significant exposure for FerriScan and complement our strategic push into the US market.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@ferriscan.com

Eva O'Malley
Company Secretary
T: +61 8 9286 5300
E: evao@ferriscan.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing core laboratory services utilising advanced medical technology for the analysis of medical images. Its patented technology FerriScan[®] provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. Initial commercialisation of FerriScan[®] has focused on pharmaceutical companies developing drug therapies to treat iron overload, and is now being extended to the broader international clinical community.